---
title: "Vyome Holdings, Inc. (HIND.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HIND.US.md"
symbol: "HIND.US"
name: "Vyome Holdings, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-21T13:42:14.166Z"
locales:
  - [en](https://longbridge.com/en/quote/HIND.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HIND.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HIND.US.md)
---

# Vyome Holdings, Inc. (HIND.US)

## Company Overview

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company’s lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.vyometx.com](https://www.vyometx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:16.000Z

**Overall: C (0.59)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 99 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -59.66% |  |
| Net Profit YoY | -577.20% |  |
| P/B Ratio | 2.20 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 14809094.08 |  |
| Revenue | 152724.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 48.66% | A |
| Profit Margin | -7157.32% | E |
| Gross Margin | 52.69% | B |
| Revenue YoY | -59.66% | E |
| Net Profit YoY | -577.20% | E |
| Total Assets YoY | 605.81% | A |
| Net Assets YoY | 271.64% | A |
| Cash Flow Margin | 45.57% | C |
| OCF YoY | -59.66% | E |
| Turnover | 0.03 | E |
| Gearing Ratio | 21.05% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Vyome Holdings, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-59.66%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-577.20%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.20",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "14809094.08",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "152724.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "48.66%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-7157.32%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "52.69%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-59.66%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-577.20%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "605.81%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "271.64%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "45.57%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-59.66%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.03",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "21.05%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.35 | 118/190 | - | - | - |
| PB | 2.20 | 96/190 | 8.01 | 6.36 | 5.73 |
| PS (TTM) | 96.97 | 150/190 | 76.73 | 52.25 | 43.25 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 50% |
| Overweight | 1 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 23.92 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/HIND.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/HIND.US/norm.md)
- [Related News](https://longbridge.com/en/quote/HIND.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/HIND.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**